Jan 21, 2021
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
Jan 05, 2021
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
Dec 28, 2020
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Dec 16, 2020
Immutep Upscales Efti Manufacturing
Dec 15, 2020
Immutep Operational Update
Dec 08, 2020
Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
Nov 17, 2020
Immutep Announces Expansion of TACTI-002 Collaboration Trial
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development
Nov 08, 2020
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
Immutep Announces Australian Patent Grant for IMP701 Antibody
Nov 01, 2020
Immutep’s TACTI-002 Data To Be Presented At Society For Immunotherapy Of Cancer 2020 Annual Meeting
Oct 29, 2020
Immutep to Collaborate with LabCorp to Develop Oncology Services and Products
Oct 22, 2020
Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients
Oct 21, 2020
Immutep Granted European Patent for IMP761
